ABP
NASDAQAbpro Holdings Inc
Price$0.52-5.50 (-91.31%)
2025-11-142026-02-20
News · 26 weeks90%
2025-12-142026-06-07
Mix090d
No activity.
Latest news
25 items- SECAbpro Holdings Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Abpro Holdings, Inc. (0001893219) (Filer)
- SECAbpro Holdings Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update8-K - Abpro Holdings, Inc. (0001893219) (Filer)
- SECSEC Form SCHEDULE 13G filed by Abpro Holdings IncSCHEDULE 13G - Abpro Holdings, Inc. (0001893219) (Subject)
- SECAbpro Holdings Inc filed SEC Form 8-K: Leadership Update8-K - Abpro Holdings, Inc. (0001893219) (Filer)
- SECAbpro Holdings Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits8-K - Abpro Holdings, Inc. (0001893219) (Filer)
- SECAbpro Holdings Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Abpro Holdings, Inc. (0001893219) (Filer)
- PRAbpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72FDA clearance enables initiation of Abpro's first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro's global collaboration with Celltrion BURLINGTON, Mass. and INCHEON, South Korea, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP), a biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced, together with its co-development partner Celltrion, Inc., that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABP-102 / CT-P72, Abpro's lead multispecific antibody oncology program. The IND clearance enables the
- SECAbpro Holdings Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Abpro Holdings, Inc. (0001893219) (Filer)
- PRAbpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive CancersIND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpro's first IND submission for a phase 1 trial in a solid tumor indication, and is being co-developed by Abpro and Celltrion, Inc. BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP, "Abpro")), a biotechnology company developing novel breakthrough therapeutics for solid tumors, together with its co-development partner Celltrion, Inc., today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA
- SECAbpro Holdings Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Abpro Holdings, Inc. (0001893219) (Filer)
- PRAbpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic ObjectivesBURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro" or the "Company"), a biotechnology company advancing next-generation antibody therapies, today announced that it has received formal notification from the Nasdaq Hearings Panel granting the Company an extension to allow additional time to regain full compliance with Nasdaq listing requirements. "We view this extension as a recognition that our compliance plan merits continued evaluation as we work to stabilize our business and build lasting momentum," said Miles Suk, Chief Executive Officer and Chairman of Abpro. "We've taken decisive steps to position the Company for sustainable growth. With
- SECSEC Form EFFECT filed by Abpro Holdings IncEFFECT - Abpro Holdings, Inc. (0001893219) (Filer)
- SECAmendment: SEC Form S-1/A filed by Abpro Holdings IncS-1/A - Abpro Holdings, Inc. (0001893219) (Filer)
- SECSEC Form 424B3 filed by Abpro Holdings Inc424B3 - Abpro Holdings, Inc. (0001893219) (Filer)
- SECSEC Form 10-Q filed by Abpro Holdings Inc10-Q - Abpro Holdings, Inc. (0001893219) (Filer)
- SECSEC Form S-1 filed by Abpro Holdings IncS-1 - Abpro Holdings, Inc. (0001893219) (Filer)
- SECAmendment: Abpro Holdings Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K/A - Abpro Holdings, Inc. (0001893219) (Filer)
- PRAbpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell EngagerCT-P72/ABP-102 poster selected as one of the Top 150 abstracts out of more than 1,300 submissions at SITC 2025 CT-P72/ABP-102 demonstrates potent and selective anti-tumor activity in HER2-high models, including Enhertu-resistant tumorsDual-affinity engineering reduces on-target, off-tumor activity and supports a favorable preclinical safety profileData supports advancement toward clinical development in HER2-positive cancers BURLINGTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Abpro Corporation (NASDAQ:ABP) ("Abpro") and Celltrion, Inc. ("Celltrion") today announced that they will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, a
- SECAbpro Holdings Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Abpro Holdings, Inc. (0001893219) (Filer)
- SECAbpro Holdings Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Abpro Holdings, Inc. (0001893219) (Filer)
- PRAbpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025Achieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune® platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq compliance and positions company for next phase of growth BURLINGTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro" or the "Company"), a biotechnology company advancing next-generation antibody therapies, today announced that its previously approved 1-for-30 reverse stock split (the "Reverse Stock Split") of its common stock became effective at 5:01 p.m. Eastern Time on October 31, 2025. The Company's common stock will begin trading on a split-adjusted basis at t
- SECAbpro Holdings Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Abpro Holdings, Inc. (0001893219) (Filer)
- SECAbpro Holdings Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Abpro Holdings, Inc. (0001893219) (Filer)
- SECAbpro Holdings Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Abpro Holdings, Inc. (0001893219) (Filer)
- SECSEC Form DEFA14A filed by Abpro Holdings IncDEFA14A - Abpro Holdings, Inc. (0001893219) (Filer)
ABP FAQ
5 questionsWhere does ABP stock trade?
Abpro Holdings Inc (ABP) is listed on NASDAQ.What sector and industry is ABP in?
Abpro Holdings Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Abpro Holdings Inc go public?
Abpro Holdings Inc (ABP) completed its IPO in 2022.What companies are similar to ABP?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ABP side-by-side with any of them on Quantisnow.How can I track ABP on Quantisnow?
Quantisnow aggregates Abpro Holdings Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABP to receive live email and push alerts on every new disclosure.